Table 4.
Baseline characteristics of progressive and non-progressive patients at year 5, based on analysis of change in EDSS score from year 1 (induction treatment termination).
| Baseline Characteristics | Non-Progressive (n = 16) |
Progressive (n = 36) |
p-Value |
|---|---|---|---|
| Gender (female/male) | 12/4 | 25/11 | >0.05 |
| Age at treatment initiation, years (mean ± SD) |
42.8 ± 9.1 | 38.9 ± 8.4 | >0.05 |
| Disease duration to treatment initiation, years (mean ± SD) | 10.1 ± 5.8 | 11.1 ± 6.0 | >0.05 |
| Cladribine (s.c.) cumulative dose at year 5 (mg/kg body weight; mean ± SD) | 2.3 ± 0.6 | 1.9 ± 0.4 | 0.02 |
| EDSS score at cladribine initiation (mean ± SD) | 4.2 ± 1.2 | 5.5 ± 1.4 | 0.03 |
EDSS, Expanded Disability Status Scale; n, number of patients; s.c., subcutaneous; SD, standard deviation.